Lixte Biotechnology Holdings, Inc. Crypto Treasury
Public CompanyUnited StatesLIXT
Never miss a treasury update
Get real-time alerts when Lixte Biotechnology Holdings, Inc. and other institutional holders change their digital asset positions.
Real-time prices · 500+ entities · Source-verified events
Total Treasury Value
$1.6M
as of 2026-04-23
Primary Asset
BTC
11.0000 held
Assets Tracked
2
digital assets
Country
United States
Public Company
Current Holdings
| Asset | Units Held | USD Value | % of Supply | Price |
|---|---|---|---|---|
| BTC | 11.0000 | $858K | 0.0001% | $78K |
| ETH | 300.0000 | $706K | 0.0002% | $2K |
Recent Treasury Events
| Date | Type | Amount | USD Value | Source |
|---|---|---|---|---|
| Jan 01, 2026 | Reclass | +300.0000 ETH | — | · Seeded from aggregated_data during Phase 3 migration. |
| Jan 01, 2026 | Reclass | +11.0000 BTC | — | · Seeded from aggregated_data during Phase 3 migration. |
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Official Website ↗
Official Website ↗